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Of evaluable pts with chimerism data, median time to 100%
donor chimerism was day 28 for CD33 and day 180 for
CD3. AGVHD occurred in 42/60 (70%) pts (grade I in 14 and
grades II-IV in 28), and cGVHD occurred in 28/52 (54%); 12
pts developed extensive cGVHD. 14 pts required donor lym-
phocyte infusion for disease progression. 100-day NRM was
10% (all from aGVHD); another 2 patients died of disease
progression. After day 100, most pts died from disease pro-
gression or infection related to cGVHD. Kaplan-Meier proba-
bilities for overall survival (OS) and progression free survival
(PFS) at one year were 61% and 48%, respectively with median
follow up of 505 days (range 31-2029). OS at 2 and 3 years was
45% and 36%. In univariate analysis, the development of
cGVHD signiﬁcantly correlated with improved OS (p  0.02)
and PFS (p  0.01). Although CD34 and CD3 doses showed
no signiﬁcant association with development of cGVHD, higher
doses of both were associated with development of aGVHD (p
 0.01 and 0.04 respectively) and higher CD34 doses (6.8 vs
9.4106/kg) were associated with development of higher grades
of aGVHD (grades II-IV versus grades 0-I) (p  0.01). Incre-
mental increases in CD34 dose were associated with an in-
creased hazard ratio for death; however, a dose above 8 106
CD34/kg was associated with lower probability of relapse (p 
0.04). NM conditioning has a role in alloPBSCT and further
investigation to optimize disease indications and CD34 dosing
is needed.
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RAPAMYCIN GENERATED DONOR TH2/TC2 CELLS PREVENT GRAFT
REJECTION BY INHIBITION OF ALLOREACTIVITY AND NOT BY DELE-
TION OF ALLOREACTIVE T CELLS
Mariotti, J.1, Foley, J.1, Wong, E.1, Borenstein, T.1, Han, S.1,
Hanson, J.1, Fowler, D.H.1 1National Cancer Institute/NIH, Bethesda,
MD.
Ex vivo rapamycin generates murine Th2 cells that potently
abrogate GVHD. We thus hypothesized that rapamycin would
generate Th2/Tc2 cells (Th2/Tc2.R cells) that prevent fully
MHC-disparate hematopoietic stem cell (HSC) rejection. To
test this hypothesis, we utilized a model of rejection involving
lethal host irradiation and quantitative host T cell addback [see
cohorts, Table]. Th2/Tc2.R cell recipients had consistent allo-
engraftment (99% donor, n9/10; rejection, n1/10); in con-
trast, control Th2/Tc2 recipients had graft rejection (n9/10)
or mixed chimerism (n1/10). Post-BMT host-vs-graft re-
sponses (HVGR) were quantiﬁed by the following method: (a)
spleen cell harvest and enumeration; (b) 24 h host (syngeneic) or
donor (allogeneic) dendritic cell stimulation; (c) cell-surface
ﬂow cytometry with anti-CD4, anti-CD8 and anti-host antibod-
ies; (d) Miltenyi IFN-gamma cytokine capture ﬂow cytometry;
and (d) calculation of absolute number of host anti-donor allo-
reactive CD4 and CD8 T cells per spleen. Graft rejection
controls had increased post-BMT allospeciﬁc CD4 and
CD8 T cells secreting IFN-g (cohort 3cohort 2; p .001).
Prevention of rejection by donor Th2/Tc2.R cells abrogated
this HVGR (cohort 5cohort 3; p .001); in contrast, donor
Th2/Tc2 cells only partially reduced HVGR (cohort 4cohort
3; p .05). Cohorts 6, 7, 8, and 9 demonstrated that rapamycin-
generated donor T cells prevention of HVGR was attributable
to both CD4 and CD8 subsets and occurred independent of
perforin or fasL molecules associated with clonal deletion
mechansims. To evaluate whether alloreactive host T cells were
clonally deleted, the fate of 2C TCR transgenic T cells utilized
as host T cell addback was evaluated [BALB/c(H-2d) into B6(H-
2b) model]. Administration of a low-dose of donor Th2/Tc2.R
cells relative to host 2C TCR transgenic cells (200:1 ratio)
resulted in actual massive expansion of alloreactive 2C cells
(cohort 13 cohort 11, p.0001), increased allospeciﬁc IFN-g
release from 2C cells, and a resultant decrease in donor chimer-
ism; in contrast, administration of high-dose Th2/Tc2.R cells
(1000:1 ratio) resulted in similar expansion of alloreactive 2C
cells, but nominal acquisition allospeciﬁc IFN-g secretion
(94.480  13.030; cohort 14 vs cohort 13, p.0005) and in-
creased donor chimerism (p.0001). Taken together, rapamy-
cin-generated Th2 or Tc2 cells prevent rejection by a mecha-
nism that reduces host allospeciﬁcity without allospeciﬁc clonal
deletion.
Th2/Tc2R Cells: Abrogation of T cell mediated HVGR without
Deletion of Host Alloreactive T cells
B6 into BALB/c (Inocula)
Absolute #
CD8IFN-g
alloreactive
host T
(x10^3/spleen)
% Donor
cells
Cohort
1 HSC - 87  1
2 Host T 18  3 -
3 HSCHost T Addback 2,600  260 46  3
4 HSCHost Tcontrol T2 980  265 75  4
5 HSCHost TT2.R 48  9 92  1
6 HSCHost TTh2.R (CD4) 284  87 92  1
7 HSCHost TTc2.R (CD8) 142  42 89  1
8 HSCHost TT2.R PFN KO 32  8 97  1
9 HSCHost TT2.R FASL KO 4  2 98  0.1
BALB/c into B6 (Inocula; 2C
TCR Host Add-back)
Absolute # of
2C TCR
Alloreactive
host T
(x10^3/spleen)
% Donor
cells
10 BM - 11  1
11 Host T 46  10 -
12 BMHost T 19  2 3  1
13 BM Host T T2.R 200:1 1,182  125 10  1
14 BM Host T T2.R 1000:1 959  68 77  2
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HYPERGLYCEMIA DURING NEUTROPENIA WAS ASSOCIATED WITH
POOR OUTCOME IN PATIENTS UNDERGOING ALLOGENEIC HEMATO-
POIETIC STEM CELL TRANSPLANTATION (HSCT)
Fuji, S.1, Kim, S.-W.1, Mori, S.-I.1, Fukuda, T.1, Kamiya, S.2,
Yamasaki, S.1, Tanosaki, R.1, Tobinai, K.1, Takaue, Y.1 1Department of
Hematology and Stem Cell Transplantation National Cancer Center
Hospital, Tsukiji, Tokyo, Japan; 2Department of Nutrition National
Cancer Center Hospital, Tsukiji, Tokyo, Japan.
Background Recipients of allogeneic HSCT frequently require
support with parenteral nutrition and immunosuppressive drugs, in
expectation of an increased risk of infections associated with hy-
perglycemia, particularly in the neutropenic period. Previous re-
ports showed that hyperglycemia was associated with morbidity
and mortality in ICU (ref van den Verge et al. N Engl J Med. 2001
Nov 8;345(19): 1359-67). There was no previous study which
assessed the clinical impact of hyperglycemia in patients undergo-
ing myeloablative HSCT. Patients and Methods A cohort of 112
consecutive adult patients with hematological malignancies treated
between January 2002 and June 2006 was reviewed retrospectively,
and 21 patients were excluded due to graft failure, preexisting
infectious diseases or preexisting neutropenia. The remaining 91
patients (Age median 35.5, 18-57) were categorized according to
mean fasting blood glucose (BG) level in the neutropenic period: 1)
“normoglycemia” (BG110 mg/dl, n28), 2) “mild hyperglyce-
mia” (110BG150 mg/dl, n49) and 3) “moderate and severe
hyperglycemia” (150 mg/dlBG, n14). Conditioning regimens
included BU/CY (n45), CY/TBI (n43) and CA/CY/TBI (n3).
GVHD prophylaxis included cyclosporine- (n62) and tacroli-
mus-based regimens (n29). Stem cell sources included bone mar-
row (n46), peripheral blood (n41) and cord blood cells (n4).
The primary endpoint of this study was the occurrence of febrile
neutropenia (FN) and infection during neutropenia. The second-
ary endpoints were parameters for organ dysfunction, aGVHD,
overall survival (OS) and treatment-related mortality (TRM). Re-
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